HUTCHMED (NASDAQ:HCM) Cut to Hold at HSBC

HSBC lowered shares of HUTCHMED (NASDAQ:HCM) from a buy rating to a hold rating in a research note published on Tuesday, MarketBeat Ratings reports.

Separately, StockNews.com upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Friday, March 21st.

HUTCHMED Stock Performance

Shares of NASDAQ HCM opened at $13.14 on Tuesday. The company’s 50-day simple moving average is $14.68 and its 200-day simple moving average is $15.33. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $21.79. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

Hedge Funds Weigh In On HUTCHMED

A number of institutional investors have recently bought and sold shares of HCM. Public Employees Retirement System of Ohio raised its stake in shares of HUTCHMED by 49.6% in the 4th quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company’s stock valued at $39,000 after acquiring an additional 899 shares during the period. Summit Trail Advisors LLC boosted its holdings in shares of HUTCHMED by 7.7% in the 1st quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company’s stock valued at $212,000 after buying an additional 1,004 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of HUTCHMED by 10.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock valued at $268,000 after buying an additional 1,799 shares in the last quarter. Barclays PLC boosted its holdings in shares of HUTCHMED by 1,483.6% in the 4th quarter. Barclays PLC now owns 2,407 shares of the company’s stock valued at $35,000 after buying an additional 2,255 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in HUTCHMED by 99.9% during the 4th quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock worth $102,000 after purchasing an additional 3,532 shares during the period. 8.82% of the stock is owned by hedge funds and other institutional investors.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.